348 related articles for article (PubMed ID: 7543719)
1. The pharmacological manipulation of fetal haemoglobin: trials using hydroxyurea and recombinant human erythropoietin.
el-Hazmi MA; al-Momen A; Warsy AS; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F
Acta Haematol; 1995; 93(2-4):57-61. PubMed ID: 7543719
[TBL] [Abstract][Full Text] [Related]
2. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
el-Hazmi MA; al-Momen A; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F; Warsy AS
Acta Haematol; 1995; 94(3):128-34. PubMed ID: 7502628
[TBL] [Abstract][Full Text] [Related]
3. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
Rodgers GP; Dover GJ; Uyesaka N; Noguchi CT; Schechter AN; Nienhuis AW
N Engl J Med; 1993 Jan; 328(2):73-80. PubMed ID: 7677965
[TBL] [Abstract][Full Text] [Related]
4. Treatment of sickle cell anemia with hydroxyurea and erythropoietin.
Goldberg MA; Brugnara C; Dover GJ; Schapira L; Charache S; Bunn HF
N Engl J Med; 1990 Aug; 323(6):366-72. PubMed ID: 1695325
[TBL] [Abstract][Full Text] [Related]
5. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
[TBL] [Abstract][Full Text] [Related]
6. Hydroxyurea and erythropoietin therapy in sickle cell anemia.
Goldberg MA; Brugnara C; Dover GJ; Schapira L; Lacroix L; Bunn HF
Semin Oncol; 1992 Jun; 19(3 Suppl 9):74-81. PubMed ID: 1379376
[TBL] [Abstract][Full Text] [Related]
7. Reticulocyte parameters and hemoglobin F production in sickle cell disease patients undergoing hydroxyurea therapy.
Borba R; Lima CS; Grotto HZ
J Clin Lab Anal; 2003; 17(2):66-72. PubMed ID: 12640630
[TBL] [Abstract][Full Text] [Related]
8. Enhancing Effect of Hydroxyurea on Hb F in Sickle Cell Disease: Ten-Year Egyptian Experience.
Youssry I; Abdel-Salam A; Ismail R; Bou-Fakhredin R; Mohamed Samy R; Ezz El-Deen F; Taher AT
Hemoglobin; 2017; 41(4-6):267-273. PubMed ID: 29251012
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyurea for the treatment of sickle cell disease.
el-Hazmi MA; Warsy AS; al-Momen A; Harakati M
Acta Haematol; 1992; 88(4):170-4. PubMed ID: 1292305
[TBL] [Abstract][Full Text] [Related]
10. Cellular effects of hydroxyurea in Hb SC disease.
Steinberg MH; Nagel RL; Brugnara C
Br J Haematol; 1997 Sep; 98(4):838-44. PubMed ID: 9326175
[TBL] [Abstract][Full Text] [Related]
11. The role of recombinant human erythropoietin in the treatment of thalassemia.
Rachmilewitz EA; Aker M
Ann N Y Acad Sci; 1998 Jun; 850():129-38. PubMed ID: 9668535
[TBL] [Abstract][Full Text] [Related]
12. Early detection of response to hydroxyurea therapy in patients with sickle cell anemia.
Ballas SK; McCarthy WF; Guo N; Brugnara C; Kling G; Bauserman RL; Waclawiw MA
Hemoglobin; 2010; 34(5):424-9. PubMed ID: 20854115
[TBL] [Abstract][Full Text] [Related]
13. Hydroxyurea increases hemoglobin F levels and improves the effectiveness of erythropoiesis in beta-thalassemia/hemoglobin E disease.
Fucharoen S; Siritanaratkul N; Winichagoon P; Chowthaworn J; Siriboon W; Muangsup W; Chaicharoen S; Poolsup N; Chindavijak B; Pootrakul P; Piankijagum A; Schechter AN; Rodgers GP
Blood; 1996 Feb; 87(3):887-92. PubMed ID: 8562958
[TBL] [Abstract][Full Text] [Related]
14. F reticulocyte response in sickle cell anemia treated with recombinant human erythropoietin: a double-blind study.
Nagel RL; Vichinsky E; Shah M; Johnson R; Spadacino E; Fabry ME; Mangahas L; Abel R; Stamatoyannopoulos G
Blood; 1993 Jan; 81(1):9-14. PubMed ID: 8417806
[TBL] [Abstract][Full Text] [Related]
15. Flow cytometric analysis of hydroxyurea effects on fetal hemoglobin production in cultures of beta-thalassemia erythroid precursors.
Amoyal I; Goldfarb A; Fibach E
Hemoglobin; 2003 May; 27(2):77-87. PubMed ID: 12779269
[TBL] [Abstract][Full Text] [Related]
16. Cooperative enhancement of F-cell formation in baboons treated with erythropoietin and hydroxyurea.
Al-Khatti A; Papayannopoulou T; Knitter G; Fritsch EF; Stamatoyannopoulos G
Blood; 1988 Aug; 72(2):817-9. PubMed ID: 2456801
[TBL] [Abstract][Full Text] [Related]
17. Combination therapy of erythropoietin, hydroxyurea, and clotrimazole in a beta thalassemic mouse: a model for human therapy.
de Franceschi L; Rouyer-Fessard P; Alper SL; Jouault H; Brugnara C; Beuzard Y
Blood; 1996 Feb; 87(3):1188-95. PubMed ID: 8562946
[TBL] [Abstract][Full Text] [Related]
18. Sickle cell anemia with systemic lupus erythematosus: response to hydroxyurea therapy.
Shetty AK; Kumar SR; Gedalia A; Warrier RP
J Pediatr Hematol Oncol; 1998; 20(4):335-7. PubMed ID: 9703008
[TBL] [Abstract][Full Text] [Related]
19. [Recombinant erythropoietin in autologous blood donation].
von Bormann B; Weidler B; Friedrich M; von Andrian-Werburg H
Anaesthesist; 1991 Jul; 40(7):386-90. PubMed ID: 1928712
[TBL] [Abstract][Full Text] [Related]
20. Effects of hydroxyurea on hemoglobin F and water content in the red blood cells of dogs and of patients with sickle cell anemia.
Orringer EP; Blythe DS; Johnson AE; Phillips G; Dover GJ; Parker JC
Blood; 1991 Jul; 78(1):212-6. PubMed ID: 1712641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
